Search Results - "Prudhon, Bernard"
-
1
Nuclear defects in skeletal muscle from a Dynamin 2-linked centronuclear myopathy mouse model
Published in Scientific reports (07-02-2019)“…Dynamin 2 (DNM2) is a key protein of the endocytosis and intracellular membrane trafficking machinery. Mutations in the DNM2 gene cause autosomal dominant…”
Get full text
Journal Article -
2
Allele‐specific silencing therapy for Dynamin 2‐related dominant centronuclear myopathy
Published in EMBO molecular medicine (01-02-2018)“…Rapid advances in allele‐specific silencing by RNA interference established a strategy of choice to cure dominant inherited diseases by targeting mutant…”
Get full text
Journal Article -
3
Development of versatile allele-specific siRNAs able to silence all the dominant dynamin 2 mutations
Published in Molecular therapy. Nucleic acids (13-09-2022)“…Dominant centronuclear myopathy (CNM) is a rare form of congenital myopathy associated with a wide clinical spectrum, from severe neonatal to milder adult…”
Get full text
Journal Article -
4
A centronuclear myopathy-dynamin 2 mutation impairs skeletal muscle structure and function in mice
Published in Human molecular genetics (15-12-2010)“…Autosomal dominant centronuclear myopathy (AD-CNM) is due to mutations in the gene encoding dynamin 2 (DNM2) involved in endocytosis and intracellular membrane…”
Get full text
Journal Article -
5
Therapy for dominant inherited diseases by allele-specific RNA interference: successes and pitfalls
Published in Current gene therapy (01-01-2015)“…RNA interference (RNAi) is a conserved mechanism for post-transcriptional gene silencing mediated by messenger RNA (mRNA) degradation. RNAi is commonly induced…”
Get more information
Journal Article -
6
Benefits of therapy by dynamin-2-mutant-specific silencing are maintained with time in a mouse model of dominant centronuclear myopathy
Published in Molecular therapy. Nucleic acids (08-03-2022)“…Dominant dynamin 2 (DNM2) mutations are responsible for the autosomal dominant centronuclear myopathy (AD-CNM), a rare progressive neuromuscular disorder…”
Get full text
Journal Article -
7
Gene Therapy via Trans-Splicing for LMNA-Related Congenital Muscular Dystrophy
Published in Molecular therapy. Nucleic acids (02-03-2018)“…We assessed the potential of Lmna-mRNA repair by spliceosome-mediated RNA trans-splicing as a therapeutic approach for LMNA-related congenital muscular…”
Get full text
Journal Article -
8
A Centronuclear Myopathy – Dynamin 2 Mutation Impairs Autophagy in Mice
Published in Traffic (Copenhagen, Denmark) (01-06-2012)“…Dynamin 2 (Dnm2) is involved in endocytosis and intracellular membrane trafficking through its function in vesicle formation from distinct membrane…”
Get full text
Journal Article -
9
Skeletal Muscle Biopsy Analysis in Reducing Body Myopathy and Other FHL1-Related Disorders
Published in Journal of neuropathology and experimental neurology (01-09-2013)“…ABSTRACTFHL1 mutations have been associated with various disorders that include reducing body myopathy (RBM), Emery-Dreifuss–like muscular dystrophy, isolated…”
Get full text
Journal Article -
10
Reprogramming the Dynamin 2 mRNA by Spliceosome-mediated RNA Trans-splicing
Published in Molecular therapy. Nucleic acids (13-09-2016)“…Dynamin 2 (DNM2) is a large GTPase, ubiquitously expressed, involved in membrane trafficking and regulation of actin and microtubule cytoskeletons. DNM2…”
Get full text
Journal Article -
11
Dynamin 2 and human diseases
Published in Journal of molecular medicine (Berlin, Germany) (01-04-2010)“…Dynamin 2 (DNM2) mutations cause autosomal dominant centronuclear myopathy, a rare form of congenital myopathy, and intermediate and axonal forms of…”
Get full text
Journal Article -
12
Dynamin 2 mutations cause sporadic centronuclear myopathy with neonatal onset
Published in Annals of neurology (01-12-2007)“…We report four heterozygous dynamin 2 (DNM2) mutations in five centronuclear myopathy patients aged 1 to 15 years. They all presented with neonatal hypotonia…”
Get full text
Journal Article -
13
Dynamin 2 mutations associated with human diseases impair clathrin-mediated receptor endocytosis
Published in Human mutation (01-10-2009)“…Dynamin 2 (DNM2) is a large GTPase involved in the release of nascent vesicles during endocytosis and intracellular membrane trafficking. Distinct DNM2…”
Get full text
Journal Article -
14
Allele-specific silencing therapy for Dynamin 2-related dominant centronuclear myopathy
Published in Circulation. Arrhythmia and electrophysiology (01-12-2017)“…Rapid advances in allele-specific silencing by RNA interference established a strategy of choice to cure dominant inherited diseases by targeting mutant…”
Get full text
Journal Article -
15
Allele‐specific silencing therapy for Dynamin 2‐related dominant centronuclear myopathy
Published in EMBO molecular medicine (15-12-2017)“…Rapid advances in allele-specific silencing by RNA interference established a strategy of choice to cure dominant inherited diseases by targeting mutant…”
Get full text
Journal Article -
16
A novel mutation in the dynamin 2 gene in a Charcot-Marie-Tooth type 2 patient: Clinical and pathological findings
Published in Neuromuscular disorders : NMD (01-04-2008)“…Abstract Mutations in dynamin 2 (DNM2) have been associated with autosomal dominant centronuclear myopathy, dominant intermediate Charcot-Marie-Tooth (CMT)…”
Get full text
Journal Article -
17
Asymmetric septal hypertrophy in heterozygous cMyBP-C null mice
Published in Cardiovascular research (01-08-2004)“…Cardiac myosin-binding protein C (cMyBP-C) gene mutations are involved in familial hypertrophic cardiomyopathy (FHC). Many of these mutations produce truncated…”
Get full text
Journal Article -
18
A NEW CENTRONUCLEAR MYOPATHY PHENOTYPE DUE TO A NOVEL DYNAMIN 2 MUTATION
Published in Neurology (06-01-2009)Get full text
Journal Article -
19
Administration of insulin-like growth factor-1 (IGF-1) improves both structure and function of delta-sarcoglycan deficient cardiac muscle in the hamster
Published in Basic research in cardiology (01-03-2005)“…Dilated cardiomyopathies (DCM) are due to progressive dilatation of the cardiac cavities and thinning of the ventricular walls and lead unavoidably to heart…”
Get full text
Journal Article -
20
Targeted inactivation of the murine cardiac myosin-binding protein C gene leads to hypertrophic cardiomyopathy
Published in Journal of molecular and cellular cardiology (01-06-2002)Get full text
Journal Article